Anixa Biosciences, Inc. Banner Image

Anixa Biosciences, Inc. has reached its limit for free report views

Work for Anixa Biosciences, Inc.? Upgrade Your Profile and unlock all your annual reports.

Anixa Biosciences, Inc.

  • Ticker ANIX
    Exchange NASDAQ More
  • Industry Diagnostic Substances More
  • Sector Healthcare More
Anixa Biosciences, Inc. Logo Image
  • 1-10 Employees
  • Based in San Jose, California
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. Anixa'sMore vaccine portfolio consists of a technology focused on the immunization against a "retired" protein, α-Lactalbumin, to prevent triple negative breast cancer (TNBC), the most lethal form of breast cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Anixa Biosciences, Inc.

Most Recent Annual Report

Anixa Biosciences, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Anixa Biosciences, Inc. has reached its limit for free report views.

Older/Archived Annual Reports